All lobbying filings

Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc. filed a Q1 report for Takeda Pharmaceuticals America Inc. on April 20, 2026.

Lobbying for Takeda Pharmaceuticals America Inc.

As filed: TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC.

All filings by Takeda Pharmaceuticals America, Inc. · Everything Takeda Pharmaceuticals America Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$1,410,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Budget/Appropriations

FY 2025 Budget Resolution - Pharmaceutical Related Provisions

Medicare/Medicaid

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act

Health Issues

Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues

Taxation/Internal Revenue Code

Administration's Global Tax Proposal General issues around 2026 Reconciliation/Inbound Concerns

Trade (domestic/foreign)

General intellectual property policy issues Issues related to proposed Tariffs - all pharmaceutical related provisions

Defense

Discussions around Supply Chain implications

Bills named in this filing 3

H.R. 1
One Big Beautiful Bill Act
S. 832
EPIC Act of 2025
H.R. 4229
To amend the Impoundment Control Act of 1974 to require prior approval from Congress before the Comptroller General may…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.